CTCL is a rare form of lymphoma of the skin. While early stages are usually confined to the
skin, later stages may spread to blood, lymph nodes and other organs. At this point, patients
usually require systemic chemo. This study will investigate the effect of everolimus as
treatment for recurrent or refractory CTCL. Participation in this study will last as long as
the study doctor believes disease has not gotten worse, and patients continue to tolerate the
study medication for a maximum of 1 year. Once off the treatment, patients will be followed
for two years.